NEW YORK, Aug. 22, 2019 /PRNewswire/ — Centinel Spine, LLC, the largest privately-held spine company focused on anterior column reconstruction, today announced that the first implantation took place in an Investigational Device Exemption (IDE) study monitored by the Food and Drug Administration (FDA). The two-level IDE clinical trial is a prospective, randomized, multi-centered clinical study evaluating two different …